Cargando…

Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives

Over the past three decades, the incidence and prevalence of neuroendocrine tumors have gradually increased. Due to the slow-growing nature of these tumors, most cases are diagnosed at advanced stages. Prognosis and survival are associated with location of primary lesion, biochemical functional stat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yau, Hanford, Kinaan, Mustafa, Quinn, Suzanne L, Moraitis, Andreas G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723116/ https://www.ncbi.nlm.nih.gov/pubmed/29255345 http://dx.doi.org/10.2147/BTT.S108818

Ejemplares similares

Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis
por: Strosberg, Jonathan R, et al.
Publicado: (2015)

Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors
por: Cheng, Yue, et al.
Publicado: (2023)

SAT-566 Avoiding the Heartache: A Case of Familial Hypercholesterolemia
por: Kinaan, Mustafa, et al.
Publicado: (2020)

Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors
por: Saif, Muhammad Wasif, et al.
Publicado: (2018)

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
por: Koumarianou, Anna, et al.
Publicado: (2012)

Exogenous Cushing Syndrome and Hip Fracture Due to Over-the-Counter Supplement (Artri King)
por: Saad-Omer, Suhail M, et al.
Publicado: (2023)

Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors
por: Al-Efraij, Khalid, et al.
Publicado: (2015)

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
por: Mercado, Moises, et al.
Publicado: (2007)

Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome
por: Moraitis, Andreas G., et al.
Publicado: (2016)

Congenital Adrenal Hyperplasia Causing Poor Response to Androgen Deprivation Therapy in Prostate Cancer
por: Kinaan, Mustafa, et al.
Publicado: (2020)

Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors
por: Wang, Yuhong, et al.
Publicado: (2017)

Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study
por: von Arx, Claudia, et al.
Publicado: (2020)

Preparation of long-acting microspheres loaded with octreotide for the treatment of portal hypertensive
por: Han, Bing, et al.
Publicado: (2021)

Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines
por: Exner, Samantha, et al.
Publicado: (2018)

Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study
por: Li, Jie, et al.
Publicado: (2016)

The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
por: Kvols, L. K., et al.
Publicado: (1992)

E4206: AMG 706 and Octreotide in Patients with Low‐Grade Neuroendocrine Tumors
por: Lubner, Sam, et al.
Publicado: (2018)

Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands
por: Hagendijk, Marije E., et al.
Publicado: (2021)

Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension
por: Cui, Pei-Jing, et al.
Publicado: (2017)

Long-Term Efficacy of S-1 Chemotherapy plus Administration of Octreotide for a Patient with Metastatic Neuroendocrine Tumor (Gastrinoma)
por: Hiraide, Sakura, et al.
Publicado: (2017)

Refractory Thrombocytopenia Responds to Octreotide Treatment in a Case of Evans Syndrome with Gastric Neuroendocrine Tumor
por: Chung-Delgado, Kocfa, et al.
Publicado: (2013)

Pharmacokinetic and technical comparison of Sandostatin(® )LAR(® )and other formulations of long-acting octreotide
por: Petersen, Holger, et al.
Publicado: (2011)

Diabetes Insipidus Induced by Combination of Short-acting Octreotide and Lanreotide for Recurrent Carcinoid Crisis of Neuroendocrine Tumour: A Case Report
por: Guan, Goh Kian, et al.
Publicado: (2021)

Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network
por: Brizzi, Maria P, et al.
Publicado: (2009)

Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis
por: Ryan, P, et al.
Publicado: (2019)

Successful use of long acting octreotide in two cases with Beckwith-Wiedemann syndrome and severe hypoglycemia
por: Al-Zubeidi, Hiba, et al.
Publicado: (2014)

The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells
por: Li, Su-Chen, et al.
Publicado: (2012)

Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study
por: Berruti, Alfredo, et al.
Publicado: (2014)

Diagnostic accuracy of technetium-99m-octreotide in imaging neuroendocrine tumors, Oman hospital experience with literature review
por: Al Bulushi, Naima, et al.
Publicado: (2019)

Octreotide Conjugates for Tumor Targeting and Imaging
por: Figueras, Eduard, et al.
Publicado: (2019)

(177)Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience
por: Satapathy, Swayamjeet, et al.
Publicado: (2021)

Efficacy of long-acting release octreotide for preventing chemotherapy-induced diarrhoea: protocol for a systematic review
por: Deng, Chao, et al.
Publicado: (2017)

Efficacy and adverse events of octreotide long-acting release in acromegaly: a real-world retrospective study
por: Zhao, Zhe, et al.
Publicado: (2022)

Octreotide Uptake in Parathyroid Adenoma
por: Karaçavuş, Seyhan, et al.
Publicado: (2012)

(68)Ga-DOTATATE PET/CT versus (111)In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective study
por: Cavicchioli, Marcelo, et al.
Publicado: (2022)

Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours
por: Laskaratos, Faidon-Marios, et al.
Publicado: (2016)

Octreotide Use in a Patient with MEN-1 Syndrome and Multifocal Pancreatic Neuroendocrine Tumors: A Case Report and Review of the Literature
por: Kemm, Matthew H., et al.
Publicado: (2019)

Long-Acting Somatostatin Analogue Safety Monitoring Protocol for Outpatients With Neuroendocrine Tumors
por: Gabrielsen, Jordan, et al.
Publicado: (2019)

Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
por: Darden, Christina, et al.
Publicado: (2021)

Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide
por: Cebon, J
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_9dmibnv77bf3v0vjakit80nbj7